2. Signaling Pathways
  3. Anti-infection
  4. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

PDF 0.94 MB

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-151269A
    SARS-CoV-2-IN-23 disodium
    		Inhibitor
    SARS-CoV-2-IN-23 disodium is a two-armed diphosphate ester and medium length molecular tweezers. SARS-CoV-2-IN-23 disodium exhibits antiviral activity with IC50s of 8.2 μM and 2.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-23 disodium induces liposomal membrane disruption with an EC50 value of 4.4 μM.
    SARS-CoV-2-IN-23 disodium
  • HY-15148S1
    Tipranavir-d7
    		Inhibitor
    Tipranavir-d7 is deuterated labeled Tipranavir (HY-15148). Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC50s of 66-410 nM. Tipranavir inhibits SARS-CoV-2 3CLpro activity.
    Tipranavir-d<sub>7</sub>
  • HY-W744206
    Azelastine-d3
    Azelastine-d3 is the deuterium labeled Azelastine (HY-B0462A). Azelastine, an antihistamine, is a potent and selective histamine 1 (H1) antagonist. Azelastine can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2.
    Azelastine-d<sub>3</sub>
  • HY-W031727S1
    Hydroxychloroquine-d5
    Hydroxychloroquine-d5 is the deuterium labeled Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro.
    Hydroxychloroquine-d<sub>5</sub>
  • HY-174224
    Amb929
    		Inhibitor
    Amb929 (ZINC000002782982), a nsp3 ligand, is an anti-SARS-CoV-2 agent. Amb929 inhibits SARS-CoV2-mNG replication in VeroE6 cells with an EC50 of 34.7 µM. Amb929 has limited and moderate cytotoxicity for VeroE6 cells (CC50: 281 µM). Amb929 also inhibits SARS-CoV-2-mNG replication in Human Airway Epithelium (HAE).
    Amb929
  • HY-148387
    SARS-CoV-2-IN-35
    		Inhibitor
    SARS-CoV-2-IN-35 is a potent and orally active SARS-CoV-2 M pro inhibitor with a Ki value of 12.1 nM. SARS-CoV-2-IN-35 can be used in research of COVID-19.
    SARS-CoV-2-IN-35
  • HY-163614
    SARS-CoV-2-IN-87
    		Inhibitor
    SARS-CoV-2-IN-87 (compound 138968421) is a potent inhibitor of methyltransferases (nsp14 and nsp16) of SARS-CoV-2.
    SARS-CoV-2-IN-87
  • HY-169997
    LU9
    		Inhibitor
    LU9 is a potent 3CLpro inhibitor with an IC50 value of 0.34 µM. LU9 has the potential for the research of SARS-CoV-2.
    LU9
  • HY-155013
    SARS-CoV-2-IN-43
    		Inhibitor
    SARS-CoV-2-IN-43 (Compound 8h) is a potentSARS-CoV-2replication inhibitor with antiviral activity.
    SARS-CoV-2-IN-43
  • HY-151274
    SARS-CoV-2-IN-28
    		Inhibitor
    SARS-CoV-2-IN-28 is a two-armed diphosphate ester with C7 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-28 exhibits antiviral activity with IC50s of 0.4 μM and 1.0 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-28 induces liposomal membrane disruption with an EC50 value of 4.4 μM.
    SARS-CoV-2-IN-28
  • HY-172214
    AB-343
    		Inhibitor
    AB-343 is a selective covalent inhibitor of SARS-CoV-2 Mpro, with an IC50 of 8 nM and a Ki of 2.8 nM. AB-343 can effectively inhibit the main proteases of SARS-CoV-2 and many other coronaviruses, and is also active against some resistant variants. AB-343 can be used in the research of treating coronavirus infection-related diseases.
    AB-343
  • HY-161844
    Virapinib
    		Inhibitor
    Virapinib is a macropinocytosis inhibitor with antiviral activities. Virapinib inhibits macropinocytosis, limiting this entry route for the viruses. Virapinib inhibits infection by SARS-CoV-2, as well as by additional viruses, such as mpox virus and TBEV.
    Virapinib
  • HY-174350
    CK2-IN-15
    		Inhibitor
    CK2-IN-15 (Compound Biv5) is a selective and potent bivalent protein kinase CK2 inhibitor with an IC50 value of 51 pM. CK2-IN-15 significantly reduces the replication of SARS-CoV-2 in HEK-ACE2-TMPRSS2 and Vero cells, and also reduces viral replication in an ex vivo model of human nasal epithelial cells. CK2-IN-15 is promising for research of β-coronavirus infection-related diseases.
    CK2-IN-15
  • HY-144464
    SARS-CoV-2 Mpro-IN-1
    		Inhibitor
    SARS-CoV-2 Mpro-IN-1 (compound 16b-3) is a potent, selective and irreversible inhibitor of SARS-CoV-2 main protease (Mpro), with an IC50 of 116 nM.
    SARS-CoV-2 Mpro-IN-1
  • HY-149362
    MTase-IN-1
    		Inhibitor
    MTase-IN-1 (compound 26) is a potent and selective inhibitor of coronavirus nsp14 N7-methyltransferases, with an IC50 of 0.72 nM. MTase-IN-1 impairs viral RNA translation and immune evasion.
    MTase-IN-1
  • HY-149774
    GC-78-HCl
    GC-78-HCl is an orally and nonpeptidic SARS-CoV-2 Mpro inhibitor, with an IC50 of 0.19 μM for enzyme. GC-78-HCl has excellent antiviral activity and favorable pharmacokinetic properties.
    GC-78-HCl
  • HY-W777545
    4-[(7-Chloro-4-quinolinyl)amino]-1-pentanol-d4
    4-[(7-Chloro-4-quinolinyl)amino]-1-pentanol-d4 is the deuterium labeled Hydroxychloroquine Impurity E (HY-131262). Hydroxychloroquine Impurity E is the impurity of Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro.
    4-[(7-Chloro-4-quinolinyl)amino]-1-pentanol-d<sub>4</sub>
  • HY-157021
    SARS-CoV-2-IN-66
    		Inhibitor
    SARS-CoV-2-IN-66 (1), a vitaminK derivative, is a SARS-CoV-2 inhibitor, with an EC50 of 70.8 μM in VeroE6/TMPRSS2 cells.
    SARS-CoV-2-IN-66
  • HY-151276A
    SARS-CoV-2-IN-29 disodium
    		Inhibitor
    SARS-CoV-2-IN-29 disodium is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-29 disodium exhibits antiviral activity with IC50s of 1.5 μM and 1.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-29 disodium induces liposomal membrane disruption with an EC50 value of 3.0 μM.
    SARS-CoV-2-IN-29 disodium
  • HY-150680
    SARS-CoV-2 nsp14-IN-1
    		Inhibitor
    SARS-CoV-2 nsp14-IN-1 (Compound 3) is a prototypic bisubstrate inhibitor of SARS-CoV-2 Nsp14 MTase with an IC50 value of 0.061 μM. SARS-CoV-2 nsp14-IN-1 (Compound 3) has an excellent selectivity profile over a panel of human methyltransferases, can against apanel of 10 human MTases including histone lysine, proteinarginine, and DNA and RNA MTases.
    SARS-CoV-2 nsp14-IN-1
Cat. No. Product Name / Synonyms Species Source